Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/161563
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Zarei, Mohammad | - |
dc.contributor.author | Pizarro Delgado, Javier | - |
dc.contributor.author | Barroso Fernández, Emma | - |
dc.contributor.author | Palomer Tarridas, Francesc Xavier | - |
dc.contributor.author | Vázquez Carrera, Manuel | - |
dc.date.accessioned | 2020-05-20T08:52:20Z | - |
dc.date.available | 2021-01-26T06:10:19Z | - |
dc.date.issued | 2020-01-26 | - |
dc.identifier.issn | 0165-6147 | - |
dc.identifier.uri | http://hdl.handle.net/2445/161563 | - |
dc.description.abstract | Nonalcoholic steatohepatitis (NASH), the severe stage of nonalcoholic fatty liver disease (NAFLD), is defined as the presence of hepatic steatosis with inflammation, hepatocyte injury, and different degrees of fibrosis. Although NASH affects 2-5% of the global population, no drug has been specifically approved to treat the disease. Fibroblast growth factor 21 (FGF21) and its analogs have emerged as a potential new therapeutic strategy for the treatment of NASH. In fact, FGF21 deficiency favors the development of steatosis, inflammation, hepatocyte damage, and fibrosis in the liver, whereas administration of FGF21 analogs ameliorates NASH by attenuating these processes. We review mechanistic insights into the beneficial and potential side effects of therapeutic approaches targeting FGF21 for the treatment of NASH. | - |
dc.format.extent | 10 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Elsevier Current Trends | - |
dc.relation.isformatof | Versió postprint del document publicat a: https://doi.org/10.1016/j.tips.2019.12.005 | - |
dc.relation.ispartof | Trends in Pharmacological Sciences, 2020, vol. 41, num. 3, p. 199-208 | - |
dc.relation.uri | https://doi.org/10.1016/j.tips.2019.12.005 | - |
dc.rights | cc-by-nc-nd (c) Elsevier Current Trends, 2020 | - |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/es | - |
dc.source | Articles publicats en revistes (Farmacologia, Toxicologia i Química Terapèutica) | - |
dc.subject.classification | Inflamació | - |
dc.subject.classification | Triglicèrids | - |
dc.subject.classification | Malalties del fetge | - |
dc.subject.classification | Obesitat | - |
dc.subject.other | Inflammation | - |
dc.subject.other | Triglycerides | - |
dc.subject.other | Liver diseases | - |
dc.subject.other | Obesity | - |
dc.title | Targeting FGF21 for the treatment of nonalcoholic steatohepatitis | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/acceptedVersion | - |
dc.identifier.idgrec | 699717 | - |
dc.date.updated | 2020-05-20T08:52:20Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
Appears in Collections: | Articles publicats en revistes (Institut de Biomedicina (IBUB)) Articles publicats en revistes (Farmacologia, Toxicologia i Química Terapèutica) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
699717.pdf | 722.79 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License